Dupilumab SAR231893 (REGN668)
LPS15023
Phase 3 small_molecule completed
Quick answer
Dupilumab SAR231893 (REGN668) for Asthma is a Phase 3 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 2 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Asthma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed